These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25298738)

  • 21. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
    Vredenburgh JJ; Desjardins A; Reardon DA; Peters KB; Herndon JE; Marcello J; Kirkpatrick JP; Sampson JH; Bailey L; Threatt S; Friedman AH; Bigner DD; Friedman HS
    Clin Cancer Res; 2011 Jun; 17(12):4119-24. PubMed ID: 21531816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials.
    Fu P; He YS; Huang Q; Ding T; Cen YC; Zhao HY; Wei X
    Mol Clin Oncol; 2016 May; 4(5):833-838. PubMed ID: 27123291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
    Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
    PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
    Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T
    J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab for the treatment of recurrent glioblastoma.
    Chamberlain MC
    Clin Med Insights Oncol; 2011; 5():117-29. PubMed ID: 21603247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma.
    Hicks MJ; Funato K; Wang L; Aronowitz E; Dyke JP; Ballon DJ; Havlicek DF; Frenk EZ; De BP; Chiuchiolo MJ; Sondhi D; Hackett NR; Kaminsky SM; Tabar V; Crystal RG
    Cancer Gene Ther; 2015 Jan; 22(1):1-8. PubMed ID: 25501993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anti-angiogenic therapy for malignant glioma].
    Nagane M
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):141-7. PubMed ID: 24743191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
    Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
    Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.
    Zhu P; Du XL; Lu G; Zhu JJ
    Oncotarget; 2017 Jul; 8(27):44015-44031. PubMed ID: 28467795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
    Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
    Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
    McGirt MJ; Than KD; Weingart JD; Chaichana KL; Attenello FJ; Olivi A; Laterra J; Kleinberg LR; Grossman SA; Brem H; Quiñones-Hinojosa A
    J Neurosurg; 2009 Mar; 110(3):583-8. PubMed ID: 19046047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab in glioblastoma multiforme.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults.
    Redjal N; Nahed BV; Dietrich J; Kalkanis SN; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):165-213. PubMed ID: 33215343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
    Goldwirt L; Beccaria K; Carpentier A; Idbaih A; Schmitt C; Levasseur C; Labussiere M; Milane A; Farinotti R; Fernandez C
    J Neurooncol; 2015 Apr; 122(2):273-81. PubMed ID: 25794638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.